CardIQ Suite vs InVision Precision Cardiac Amyloid

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

CardIQ Suite

by GE HealthCare

InVision Precision Cardiac Amyloid

by InVision Medical Technology Corporation

AI Verdict

These tools are adjacent competitors, both focusing on cardiology AI but with distinct applications. CardIQ Suite specializes in cardiac CT post-processing for comprehensive cardiovascular disease diagnosis, including calcium scoring and CCTA review. InVision Precision Cardiac Amyloid, on the other hand, is an AI-powered echocardiography tool specifically designed for the early detection of cardiac amyloidosis.

Choose CardIQ Suite if…

Choose CardIQ Suite if your practice primarily utilizes cardiac CT scans and requires an integrated, automated solution for comprehensive cardiovascular disease diagnosis and treatment planning. This tool excels in automated calcium scoring, CCTA review, and detailed visualization of coronary vasculature, aiding in the assessment of coronary artery disease, functional parameters of the heart, and follow-up for stent placement.

View CardIQ Suite →

Choose InVision Precision Cardiac Amyloid if…

Choose InVision Precision Cardiac Amyloid if your cardiology practice focuses on echocardiography and aims to improve the early detection and diagnosis of cardiac amyloidosis. This AI-powered software is specifically designed to evaluate transthoracic echocardiogram studies for both AL and ATTR Cardiac Amyloidosis, aiding clinicians in assessing patients with heart failure symptoms and reducing misdiagnosis.

View InVision Precision Cardiac Amyloid →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	CardIQ Suite	InVision Precision Cardiac Amyloid
Pricing	Unknown	Subscription
Deployment	On-premise (integrated with CT systems)	Software as a Medical Device (SaMD), integrated into clinical workflows for echocardiography labs.
FDA Status	Cleared AI-estimated	1 AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

CardIQ Suite

CardIQ Suite emphasizes an integrated workflow for seamless review of calcium scoring and CCTA data, with features like cine capability and double oblique tools for detailed visualization. This focus on a comprehensive and efficient workflow suggests a strong emphasis on user experience within a radiology context.

Clinical Value

InVision Precision Cardiac Amyloid

InVision Precision Cardiac Amyloid focuses on earlier detection of a life-threatening and often underdiagnosed disease, cardiac amyloidosis, which can significantly improve patient outcomes. It has strong clinical validation, with peer-reviewed publications in JAMA Cardiology and an ongoing prospective multi-center clinical trial.

Pricing & Value

InVision Precision Cardiac Amyloid

InVision Precision Cardiac Amyloid offers transparent subscription-based pricing starting at $49/month, with enterprise options available. This transparency and lower entry point provide clear value, especially for smaller practices or those looking to pilot the technology. CardIQ Suite only states 'contact for pricing', which offers less transparency.

Enterprise Readiness

CardIQ Suite

CardIQ Suite, as a GE Medical Systems SCS product, is deployed on-premise with GE Advantage Workstation (AW) and AW Server (AWS), indicating a robust integration within existing enterprise imaging infrastructure. Its comprehensive suite of tools for various cardiac CT post-processing tasks also suggests a broader applicability within a large healthcare system.

Innovation

Tie

Both tools leverage AI and deep learning for advanced cardiac analysis. CardIQ Suite utilizes deep learning for automated calcium scoring and coronary artery territory labeling. InVision Precision Cardiac Amyloid uses AI for the detection of a complex and often missed condition from echocardiograms, with evidence-based algorithms and FDA Breakthrough Device Designation. Both demonstrate significant innovation within their respective domains.

Support & Docs

CardIQ Suite

GE Healthcare, as a larger and more established company, offers a comprehensive customer documentation portal with user manuals, technical service documents, and support resources. While InVision Medical Technology mentions integration into clinical workflows, specific details on their support and documentation offerings are less explicit in the provided information.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	CardIQ Suite	InVision Precision Cardiac Amyloid
Tool Name	CardIQ Suite	InVision Precision Cardiac Amyloid
Company	GE Medical Systems SCS	InVision Medical Technology Corporation
Description	AI-powered cardiac CT post-processing application, offering automated calcium scoring and CCTA review for comprehensive cardiovascular disease diagnosis and treatment planning.	AI-powered software for echocardiography to detect cardiac amyloidosis, aiming for earlier detection and improved patient outcomes.
Primary Modality	Cardiac CT	Echocardiography
Key Feature Focus	Automated Calcium Score, CCTA Review, Plaque ID	AI-powered detection of cardiac amyloidosis

Videos

Demos, reviews, and walkthroughs featuring CardIQ Suite and InVision Precision Cardiac Amyloid.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

How do these tools integrate into existing clinical workflows and EHR systems?

CardIQ Suite offers an integrated workflow for reviewing calcium scoring and CCTA data, and its results can be exported as DICOM SR, batch axial SCPT, or PDF reports for integration into structured reporting templates. InVision Precision Cardiac Amyloid is designed as a Software as a Medical Device (SaMD) that integrates into clinical workflows for echocardiography labs, deploying alongside existing PACS, Epic EHR, and structured reporting platforms without requiring new hardware or scanners.

What is the accuracy and sensitivity of each tool for its specific application?

CardIQ Suite demonstrates high accuracy in identifying coronary artery calcifications (>95% correct identification) and accurately labeling coronary artery territories (>90%). InVision Precision Cardiac Amyloid, in a validation study of 1,221 echocardiogram studies, showed a sensitivity of 60.7% and a specificity of 99.0% for detecting cardiac amyloidosis.

What is the learning curve for physicians and how much support is available?

While specific details on the learning curve for CardIQ Suite are not provided, its integrated workflow and automated features suggest a focus on efficiency. InVision Precision Cardiac Amyloid is designed to integrate into existing clinical workflows, aiming for zero marginal clinician burden, suggesting a low learning curve for physicians. Both companies would likely offer support, but specific details on support quality are not available in the provided information.

What clinical context is most relevant for a physician choosing between these tools?

CardIQ Suite is designed for comprehensive cardiovascular disease diagnosis and treatment planning using cardiac CT, offering automated calcium scoring and CCTA review, and aiding in the diagnosis of coronary artery disease, functional parameters, and follow-up for stents and bypasses. InVision Precision Cardiac Amyloid focuses on the early detection of cardiac amyloidosis from echocardiograms, a life-threatening and often underdiagnosed disease, and is particularly relevant for patients with heart failure symptoms, especially those over 65 years old.

What are the considerations for rolling out these tools across multiple sites?

CardIQ Suite is an on-premise solution, deployed on GE Advantage Workstation (AW) and AW Server (AWS), which would necessitate individual installations and configurations at each site. InVision Precision Cardiac Amyloid, as a Software as a Medical Device (SaMD) that integrates with existing PACS and EHR systems, is designed for a single deployment path that can grow across a cardiovascular service line, potentially simplifying multi-site rollouts.

What audit-trail features are available to track the AI's contribution to diagnosis?

For CardIQ Suite, DICOM conformance statements indicate that values can be set directly by the application or generated by the system, and attributes can be copied from the modality worklist or entered by the user, implying a level of data traceability. InVision Precision Cardiac Amyloid processes echocardiogram videos and generates a report suggestive or not suggestive of cardiac amyloidosis, which serves as an adjunctive diagnostic aid, and its output is intended to alert physicians for further investigations.